Clinical trials: Pneumococcal Vaccine
Invasive Pneumococcal Disease
Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.
The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)
- Trial name
- NCT00227188
- Testing
- Pneumococcal 7-valent conjugate vaccine Prevnar
- Where
- Spain
- Volunteers
- 408 people
- Sponsor
- Pfizer
Recurrent Acute Otitis Media
Pneumococcal Vaccination of Otitis-prone Children
Acute otitis media (AOM) is a common childhood disease, which becomes recurrent in 15-20% of the cases. Streptococcus pneumoniae is one of the leading causative agents, and a small reduction in the number of AOM episodes has been…
- Trial name
- NCT01263210
- Testing
- Prevenar
- Where
- Sweden
- Volunteers
- 109 people
- Sponsor
- Lund University Hospital
Asplenia, β-thalassemia Major
B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals
The purpose of this study is to determine whether one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) induces immunological memory in asplenic adults and whether previously administered immunizations with the…
- Trial name
- NCT01846923
- Testing
- PCV13
- Where
- Greece
- Volunteers
- 37 people
- Sponsor
- Aghia Sophia Children's Hospital of Athens
Healthy Volunteers
Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV
This is a randomized, open-label, placebo-controlled phase 1 study in healthy adult volunteers to provide information regarding vaccination with a common pneumococcal polysaccharide vaccine while receiving efgartigimod.
- Trial name
- NCT05163834
- Testing
- Efgartigimod, PNEUMOVAX 23
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- argenx
Pneumococcal Infectious Disease
A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population
An open clinical trial of a 23-valent pneumococcal polysaccharide vaccine (PPV23) developed by Sinovac Life Science Co., Ltd was conducted to evaluate the safety of Sinovac PPV23 in target population of individuals aged 2 years…
- Trial name
- NCT07071701
- Testing
- 23-valent pneumococcal polysaccharide vaccine, Influenza vaccine
- Where
- China
- Volunteers
- 19,267 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Acute Otitis Media (AOM)
Safety and Efficacy of wSp Vaccine in Young Children
The goal of this clinical trial is to evaluate whether the wSp vaccine can prevent nasopharyngeal colonization by pneumococcal bacteria in healthy young children who have received routine PCV15 or PCV20 vaccination.
- Trial name
- wSp005 (NCT07216430)
- Testing
- wSp vaccine, Saline (0.9% NaCl)
- Where
- 7 sites in United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Serum Life Science Europe GmbH
Pulmonary Disease, Chronic Obstructive
Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease
Pneumococcal disease is a serious bacterial infection that can affect different parts of the body, including the lungs. People with chronic illnesses, such as chronic obstructive pulmonary disease (COPD), have a greater risk of…
- Trial name
- PNEUMO (NCT00457977)
- Testing
- Pneumovax (PPSV23), Prevnar (PCV7)
- Where
- 18 sites in United States
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Healthy Volunteers
Consistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate Vaccine
The objective of this clinical trial is to evaluate the consistency of the 15-valent pneumococcal conjugate vaccine in three batches of the 3-month-old population, as well as the immunogenicity and safety of vaccination in the…
- Trial name
- NCT05939219
- Testing
- 15-valent pneumococcal conjugate vaccine 202210001, 15-valent pneumococcal conjugate vaccineY202210002, 15-valent pneumococcal conjugate vaccineY202210003
- Where
- China
- Volunteers
- 2,346 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Pneumococcal Infections, Streptococcus Pneumoniae Infections
Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults
This study is designed to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adult volunteers.
- Conditions
- Pneumococcal Infections, Streptococcus Pneumoniae Infections, Pneumococcal Pneumonia
- Trial name
- NCT01444352
- Testing
- Pneumococcal vaccine Formulation 1, Pneumococcal vaccine Formulation 2, Pneumococcal vaccine Formulation 3
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Infections
Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly
The purpose of this study is to evaluate the immunogenicity and safety of an investigational 23-valent pneumococcal polysaccharide vaccine (PPV) in healthy children, adults and elderly.
- Trial name
- NCT02451969
- Testing
- investigational 23-valent PPV, control 23-valent PPV
- Where
- China
- Volunteers
- 1,760 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Lymphoma
Higher Infused Lymphocyte Counts Improve Antibody Response to Immunization After Autologous Stem Cell Transplantation
The purpose of this study is to determine if higher absolute lymphocyte count in the infused stem cell autograft (A-ALC) will lead to an improved antibody response to post-transplant immunization with Pneumococcal Conjugate…
- Trial name
- NCT00889278
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Adverse Effects
Pneumococcal Protein Vaccine Safety and Immunogenicity Trial
This is an observer-blind, randomised, vaccine-controlled, vaccine trial to determine the safety and immunogenicity of a pneumococcal protein vaccine.
- Trial name
- PPR02 (NCT01764126)
- Testing
- Pneumococcal protein vaccine
- Where
- Bangladesh
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Pneumococcal Infection
A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants
The purpose of this study is to evaluate the safety and immunogenicity of LBVE (Multivalent Pneumococcal Conjugate Vaccine) in healthy infants.
- Trial name
- NCT03467984
- Testing
- LBVE, Prevnar13
- Where
- South Korea
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- LG Chem
Pneumonia, Meningitis
Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Lung Fluid of Adults With and Without HIV Infection
Lung immune responses are regulated independently of systemic responses. Injected vaccines may induce optimal responses in blood but not at mucosal surfaces.
- Conditions
- Pneumonia, Meningitis, Invasive Pneumococcal Disease, HIV
- Trial name
- NCT00371878
- Testing
- 7-valent pneumococcal conjugate vaccine (Prevnar)
- Where
- Malawi
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Royal Liverpool University Hospital
Pneumonia, Pneumococcal, Pneumonia Childhood
Paediatric Pneumococcal Pneumonia in Malaysia Prior to and During Pneumococcal Conjugate Vaccine (PCV) Implementation
The purpose of this research is to provide baseline surveillance of pneumonia in young children in Malaysia before and during the implementation of the pneumococcal conjugate vaccine (PCV).
- Trial name
- MSIP PCV (NCT04923035)
- Where
- 3 sites in Malaysia
- Volunteers
- 1,010 people, healthy volunteers welcome
- Sponsor
- IMU University, Malaysia
Acute Otitis Media
Assessment of the Natural Antibody Response to Pneumococcal Surface Proteins During Acute Otitis Media in Children
This clinical study is designed to assess prospectively the sero-responses to various proteins in cases of pneumococcal Acute Otitis Media.
- Trial name
- NCT01214538
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- NasVax Ltd
HIV Infections
A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART
To ascertain the effect of thalidomide on immune responses to vaccination with polyvalent pneumococcal polysaccharide vaccine and tetanus toxoid in HIV-infected patients; particularly, on markers of immune activation and…
- Trial name
- NCT00002392
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rockefeller University
COVID-19, Pneumococcal Infections
Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years
Vaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults aged over 60 or 65 years (depending local guidelines) who have never received a pneumococcal vaccine or…
- Trial name
- NVX_PCV20 (NCT05767606)
- Testing
- NVX, PCV20
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Pneumococcal Infectious Disease
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday).
- Trial name
- NCT06617715
- Testing
- Sinovac PCV13, Prevnar®
- Where
- China
- Volunteers
- 3,080 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Conjugate Vaccine
Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort
The purpose of this study is to assess the "late" immune response to further doses of pneumococcal conjugate vaccine more than 10 years after primary immunization with Prevnar (7vPnC) in infancy, as compared with individuals who…
- Trial name
- PILOT (NCT00824850)
- Testing
- 13-valent Pneumococcal Conjugate Vaccine
- Where
- 2 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Pfizer